Search

Your search keyword '"Robb, Merlin"' showing total 1,577 results

Search Constraints

Start Over You searched for: Author "Robb, Merlin" Remove constraint Author: "Robb, Merlin"
1,577 results on '"Robb, Merlin"'

Search Results

1. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum

2. HIV incidence and its associated factors among young adults with multiple sexual partners in Maputo, Mozambique: a vaccine preparedness study

3. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

4. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

5. The Association Between Heterosexual anal Intercourse and HIV Acquisition in Three Prospective Cohorts of Women

6. Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial

7. Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial

8. Transmission of highly virulent CXCR4 tropic HIV-1 through the mucosal route in an individual with a wild-type CCR5 genotype

9. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

10. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

11. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

12. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

13. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study

14. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

15. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

16. Risk of COVID-19 after natural infection or vaccination

17. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

18. Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria

21. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

22. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.

23. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection

24. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma

25. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

26. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa

27. Determinants of Preexposure Prophylaxis Cascade Among Sexual and Gender Minorities in Nigeria

28. Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

29. Acute HIV-1 infection viremia associate with rebound upon treatment interruption

30. Dissecting drivers of immune activation in chronic HIV-1 infection

31. CD16 and CD57 expressing gamma delta T cells in acute HIV-1 infection are associated with the development of neutralization breadth.

32. Initial productive and latent HIV infections originate in vivo by infection of resting T cells

33. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

34. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

35. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

37. Brain volumetrics differ by Fiebig stage in acute HIV infection

38. Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand

39. Computational analysis of antibody dynamics identifies recent HIV-1 infection

40. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection

41. Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers

42. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response

43. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

44. B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies

45. Prospective longitudinal study of men who have sex with men and transgender women to determine HIV incidence in two provinces in Thailand.

46. Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria

47. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

48. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection

50. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

Catalog

Books, media, physical & digital resources